Kuria Therapeutics to Present at 2023 Ophthalmology Futures Retina Forum
- Kuria's Chief Executive Officer Dr. Keith Ward to discuss preclinical proof-of-concept data in dry AMD and Kuria's development plans...
top of page
Mitochondrial Dysfunction is a
ROOT CAUSE of Blinding Diseases
Vision has high ATP requirements
In the retina, ATP drives the visual cycle in the retinal pigment epithelium, photoreceptors, and neural retina. In the cornea, ATP powers endothelial cell pumps to keep the cornea clear.
While managing
constant ROS insult
Reactive oxygen species (ROS) are created in the retina by high oxygen tension in the choriocapillaris and in the cornea by constant exposure to UV light.
Nrf2 is a MASTER REGULATOR
of Mitochondrial Function
Nrf2 activation
Increases mitochondrial function and detoxifies ROS which may be beneficial in a broad array of ophthalmic diseases.
Kuria has a PORTFOLIO
of patented Nrf2 activators
These activators increase expression of target protein in eye tissues, including retinal pigment epithelium, corneal endothelium, corneal stroma, corneal epithelium, lens epithelium, ciliary body, and trabecular meshwork.
Pipeline
Kuria will initiate 3 clinical programs, with 2 product candidates, within 12 months from funding.
Learn More
View our CEO's company presentation for the 2023 Ophthalmology Futures European Forum (Vienna, Austria)
Team
Contact
bottom of page